Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
T-cell Lymphomas|Relapsed or Refractory
DRUG: Carfilzomib|DRUG: Romidepsin|DRUG: Lenalidomide
Maximum Tolerated Dose of Romidepsin, Determine the MTD by NCI-CTCAE v4.0., 21 days|Maximum Tolerated Dose of Lenalidomide, Determine the MTD by NCI-CTCAE v4.0., 21 days|Maximum Tolerated Dose of Carfilzomib, Determine the MTD by NCI-CTCAE v4.0., 21 days
Overall Response Rate (Orr) at the Maximum Tolerated Dose, will be summarized using percentages and confidence intervals will be provided. ORR will be calculated based on the best response at any time during the course of treatment on this protocol., 1 year
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.